Alkermes initiates phase 3 trials for narcolepsy drug alixorexton

April 1, 2026 7:00 AM

Alkermes plc (NASDAQ: ALKS) announced the initiation of its phase 3 Brilliance Studies program evaluating alixorexton for treating narcolepsy type ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found